Tixagevimab-cilgavimab (AZD7442) for the treatment of patients hospitalized with COVID-19 (DisCoVeRy): A phase 3, randomized, double-blind, placebo-controlled trial

Summary

This is a publication. If there is no link to the publication on this page, you can try the pre-formated search via the search engines listed on this page.

Authors: Maya Hites, Clément R. Massonnaud, Eva Larranaga Lapique, Drifa Belhadi, Simon Jamard, François Goehringer, François Danion, Jean Reignier, Nathalie de Castro, Denis Garot, Karine Lacombe, Violaine Tolsma, Emmanuel Faure, Denis Malvy, Thérèse Staub, Johan Courjon, France Cazenave-Roblot, Anne Ma Dyrhol Riise, Paul Leturnier, Guillaume Martin-Blondel, Claire Roger, Karolina Akinosoglou, Vincen

Journal title: Journal of Infection

Journal number: 88

Journal publisher: W. B. Saunders Co., Ltd.

Published year: 2024

Published pages: 106120

DOI identifier: 10.1016/j.jinf.2024.106120

ISSN: 0163-4453